Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.
- The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.
- Additional data on the initial cohorts in the DesCAARTes trial are anticipated to be presented at medical meetings and/or scientific sessions in 2022.
- Cabalettas DesCAARTes Phase 1 trial is an open-label, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
- For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).